Seattle Genetics CEO explains how Adcetris kills cancer and could make billions of dollars

Seattle Genetics is the largest biotechnology company in the Puget Sound region, with more than 900 employees and a current market capitalization of $8.3 billion. Its flagship drug, Adcetris, is already approved and on the market to treat three types of lymphoma in patients who have undergone cancer treatment. The drug generated $226 million in 2015 sales. Seattle Genetics co-founder, President and CEO Clay Siegall says future iterations of Adcetris could be transformative for the company. What…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news